379 related articles for article (PubMed ID: 25367749)
21. False-positive findings on 6-[18F]fluor-l-3,4-dihydroxyphenylalanine PET (
Berends AMA; Kerstens MN; Bolt JW; Links TP; Korpershoek E; de Krijger RR; Walenkamp AME; Noordzij W; van Etten B; Kats-Ugurlu G; Brouwers AH; van der Horst-Schrivers ANA
Eur J Endocrinol; 2018 Aug; 179(2):125-133. PubMed ID: 29875288
[TBL] [Abstract][Full Text] [Related]
22. The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas.
Taïeb D; Tessonnier L; Sebag F; Niccoli-Sire P; Morange I; Colavolpe C; De Micco C; Barlier A; Palazzo FF; Henry JF; Mundler O
Clin Endocrinol (Oxf); 2008 Oct; 69(4):580-6. PubMed ID: 18394015
[TBL] [Abstract][Full Text] [Related]
23. PET/CT using ¹⁸F-FDOPA provides improved staging of carcinoid tumor patients in a Canadian setting.
Yakemchuk VN; Jager PL; Chirakal R; Reid R; Major P; Gulenchyn KY
Nucl Med Commun; 2012 Mar; 33(3):322-30. PubMed ID: 22183015
[TBL] [Abstract][Full Text] [Related]
24. Can (18)F-FDOPA PET/CT predict survival in patients with suspected recurrent glioma? A prospective study.
Karunanithi S; Sharma P; Kumar A; Gupta DK; Khangembam BC; Ballal S; Kumar R; Kumar R; Bal C
Eur J Radiol; 2014 Jan; 83(1):219-25. PubMed ID: 24191944
[TBL] [Abstract][Full Text] [Related]
25. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas.
Imani F; Agopian VG; Auerbach MS; Walter MA; Imani F; Benz MR; Dumont RA; Lai CK; Czernin JG; Yeh MW
J Nucl Med; 2009 Apr; 50(4):513-9. PubMed ID: 19289420
[TBL] [Abstract][Full Text] [Related]
26. 18F-FDOPA PET/CT for detection of recurrence in patients with glioma: prospective comparison with 18F-FDG PET/CT.
Karunanithi S; Sharma P; Kumar A; Khangembam BC; Bandopadhyaya GP; Kumar R; Gupta DK; Malhotra A; Bal C
Eur J Nucl Med Mol Imaging; 2013 Jul; 40(7):1025-35. PubMed ID: 23525498
[TBL] [Abstract][Full Text] [Related]
27. Head-to-head comparison between
Heimburger C; Veillon F; Taïeb D; Goichot B; Riehm S; Petit-Thomas J; Averous G; Cavalcanti M; Hubelé F; Chabrier G; Namer IJ; Charpiot A; Imperiale A
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):979-987. PubMed ID: 28050631
[TBL] [Abstract][Full Text] [Related]
28. 18F-DOPA PET and enhanced CT imaging for congenital hyperinsulinism: initial UK experience from a technologist's perspective.
Meintjes M; Endozo R; Dickson J; Erlandsson K; Hussain K; Townsend C; Menezes L; Bomanji J
Nucl Med Commun; 2013 Jun; 34(6):601-8. PubMed ID: 23571817
[TBL] [Abstract][Full Text] [Related]
29.
Tuzcu SA; Pekkolay Z; Kılınç F; Tuzcu AK
J Nucl Med Technol; 2017 Sep; 45(3):198-200. PubMed ID: 28798227
[TBL] [Abstract][Full Text] [Related]
30. Role of PET/CT and Therapy Management of Pancreatic Neuroendocrine Tumors.
Calabrò D; Argalia G; Ambrosini V
Diagnostics (Basel); 2020 Dec; 10(12):. PubMed ID: 33297381
[TBL] [Abstract][Full Text] [Related]
31. Adrenal tracer uptake by
Noordzij W; Glaudemans AWJM; Schaafsma M; van der Horst-Schrivers ANA; Slart RHJA; van Beek AP; Kerstens MN
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1560-1566. PubMed ID: 31011769
[TBL] [Abstract][Full Text] [Related]
32. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy.
Chen W; Silverman DH; Delaloye S; Czernin J; Kamdar N; Pope W; Satyamurthy N; Schiepers C; Cloughesy T
J Nucl Med; 2006 Jun; 47(6):904-11. PubMed ID: 16741298
[TBL] [Abstract][Full Text] [Related]
33. Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases.
Archier A; Varoquaux A; Garrigue P; Montava M; Guerin C; Gabriel S; Beschmout E; Morange I; Fakhry N; Castinetti F; Sebag F; Barlier A; Loundou A; Guillet B; Pacak K; Taïeb D
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1248-57. PubMed ID: 26637204
[TBL] [Abstract][Full Text] [Related]
34. Comparative diagnostic accuracy of contrast-enhanced MRI and (18)F-FDOPA PET-CT in recurrent glioma.
Karunanithi S; Sharma P; Kumar A; Khangembam BC; Bandopadhyaya GP; Kumar R; Goenka A; Gupta DK; Malhotra A; Bal C
Eur Radiol; 2013 Sep; 23(9):2628-35. PubMed ID: 23624623
[TBL] [Abstract][Full Text] [Related]
35. Added value of early 18F-FDOPA PET/CT acquisition time in medullary thyroid cancer.
Soussan M; Nataf V; Kerrou K; Grahek D; Pascal O; Talbot JN; Montravers F
Nucl Med Commun; 2012 Jul; 33(7):775-9. PubMed ID: 22546877
[TBL] [Abstract][Full Text] [Related]
36. Epiglottic Squamous Cell Carcinoma Showing Unexpected 18F-FDOPA Uptake on PET/CT Investigation.
Dietemann S; Debry C; Onea A; Namer IJ; Imperiale A
Clin Nucl Med; 2015 Jul; 40(7):e370-1. PubMed ID: 26018705
[TBL] [Abstract][Full Text] [Related]
37. Prospective comparison of (99m)Tc-GH SPECT/CT and (18)F-FDOPA PET/CT for detection of recurrent glioma: a pilot study.
Karunanithi S; Bandopadhyaya GP; Sharma P; Kumar A; Singla S; Malhotra A; Gupta DK; Bal C
Clin Nucl Med; 2014 Feb; 39(2):e121-8. PubMed ID: 23579970
[TBL] [Abstract][Full Text] [Related]
38. Integrated whole-body PET/MRI with 18F-FDG, 18F-FDOPA, and 18F-FDA in paragangliomas in comparison with PET/CT: NIH first clinical experience with a single-injection, dual-modality imaging protocol.
Blanchet EM; Millo C; Martucci V; Maass-Moreno R; Bluemke DA; Pacak K
Clin Nucl Med; 2014 Mar; 39(3):243-50. PubMed ID: 24152658
[TBL] [Abstract][Full Text] [Related]
39. Clinical utility of functional imaging with ¹⁸F-FDOPA in Von Hippel-Lindau syndrome.
Weisbrod AB; Kitano M; Gesuwan K; Millo C; Herscovitch P; Nilubol N; Linehan WM; Kebebew E
J Clin Endocrinol Metab; 2012 Apr; 97(4):E613-7. PubMed ID: 22259055
[TBL] [Abstract][Full Text] [Related]
40. Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine.
Becherer A; Karanikas G; Szabó M; Zettinig G; Asenbaum S; Marosi C; Henk C; Wunderbaldinger P; Czech T; Wadsak W; Kletter K
Eur J Nucl Med Mol Imaging; 2003 Nov; 30(11):1561-7. PubMed ID: 14579097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
